Spyre Therapeutics, Inc.
86.93USD
-3.8600 (-4.25%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.3M | 886.0K | 0.0 | 0.0 | 0.0 | 0.0 |
| Q1 | 1.4M | 198.0K | 0.0 | — | — | — |
| Q2 | 625.0K | 688.0K | 0.0 | — | — | — |
| Q3 | 174.0K | 0.0 | 0.0 | — | 0.0 | — |
| Q4 | 168.0K* | 0.0* | 0.0* | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.78 | 1.97 | — | — | -2.88 | -3.52 |
| Q1 | -.529 | -.382 | .514 | — | -.106 | — |
| Q2 | -.463 | 3.18 | .590 | — | -.050 | — |
| Q3 | -.346 | .123 | 1.06 | -.021 | -.833 | — |
| Q4 | -.399* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -1.31* |
| — |
| — |
| -.873 |
| — |